The goal of this observational study is to learn how intravenous lipid emulsions may affect blood clotting function in hospitalized patients. The main question it aims to answer is: Does receiving intravenous lipid emulsions change blood clotting function in hospitalized patients? Inpatients who received intravenous lipid emulsions as part of their regular medical care during hospitalization will be included in this study. Information about their blood clotting function before and after lipid emulsion use will be collected from existing hospital records and compared with patients who did not receive lipid emulsions. This study will not change or add to the medical care patients receive.
Study Type
OBSERVATIONAL
Enrollment
6,259
Receiving intravenous lipid emulsions as part of routine hospital care.
Department of Pharmacy, Xiangya Hospital, Central South University
Changsha, Hunan, China
Platelet Count (PLT)
Platelet count measured by routine hematology testing to assess platelet levels involved in hemostasis and thrombosis.
Time frame: During hospitalization (an average of 18 days)
Coagulation Time Parameters (PT, APTT, and TT)
Prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT) measured by routine coagulation testing.
Time frame: During hospitalization (an average of 18 days)
Fibrinogen (FIB)
Plasma fibrinogen concentration measured by routine coagulation testing to assess clotting factor levels involved in fibrin formation.
Time frame: During hospitalization (an average of 18 days)
D-dimer (DD)
Plasma D-dimer level measured by routine laboratory testing to assess fibrin degradation and activation of the coagulation and fibrinolytic systems.
Time frame: During hospitalization (an average of 18 days)
Fibrin/Fibrinogen Degradation Products (FDPs)
Fibrin and fibrinogen degradation products measured by routine laboratory testing to evaluate fibrinolytic activity.
Time frame: During hospitalization (an average of 18 days)
Hemoglobin (Hb)
Hemoglobin concentration measured by routine hematology testing.
Time frame: During hospitalization (an average of 18 days)
Total Bilirubin (TBil)
Total bilirubin level measured by routine biochemical testing to assess bilirubin metabolism and liver function.
Time frame: During hospitalization (an average of 18 days)
Direct Bilirubin (DBil)
Direct bilirubin level measured by routine biochemical testing as an indicator of conjugated bilirubin metabolism and hepatobiliary function.
Time frame: During hospitalization (an average of 18 days)
Aspartate Aminotransferase (AST)
Aspartate aminotransferase measured by routine biochemical testing as a marker of hepatocellular injury.
Time frame: During hospitalization (an average of 18 days)
Alanine Aminotransferase (ALT)
Alanine aminotransferase measured by routine biochemical testing to assess liver function.
Time frame: During hospitalization (an average of 18 days)
Serum Creatinine (Scr)
Serum creatinine level measured by routine biochemical testing to evaluate renal function.
Time frame: During hospitalization (an average of 18 days)
Blood Urea Nitrogen (BUN)
Blood urea nitrogen measured by routine biochemical testing to assess renal function and nitrogen metabolism.
Time frame: During hospitalization (an average of 18 days)
Serum Albumin (ALB)
Serum albumin concentration measured by routine biochemical testing to evaluate nutritional and hepatic status.
Time frame: During hospitalization (an average of 18 days)
Total Protein (TP)
Total protein concentration measured by routine biochemical testing to assess overall protein metabolism.
Time frame: During hospitalization (an average of 18 days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.